{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T01:26:57Z","timestamp":1767922017987,"version":"3.49.0"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273760"],"award-info":[{"award-number":["82273760"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007162","name":"Department of Science and Technology of Guangdong Province","doi-asserted-by":"publisher","award":["2021B0909050003"],"award-info":[{"award-number":["2021B0909050003"]}],"id":[{"id":"10.13039\/501100007162","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["23YF1456900"],"award-info":[{"award-number":["23YF1456900"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ejmech.2025.117768","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T19:10:36Z","timestamp":1747422636000},"page":"117768","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Discovery of potent anti-idiopathic pulmonary fibrosis (IPF) agents based on an o-aminopyridinyl alkynyl scaffold"],"prefix":"10.1016","volume":"294","author":[{"given":"Yang","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenhui","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yihao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0711-2681","authenticated-orcid":false,"given":"Youhong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1896-4188","authenticated-orcid":false,"given":"Likun","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3990-0508","authenticated-orcid":false,"given":"Zhicheng","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.117768_bib1","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(11)60052-4","article-title":"Idiopathic pulmonary fibrosis","volume":"378","author":"King","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2025.117768_bib2","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMra1705751","article-title":"Idiopathic pulmonary fibrosis","volume":"378","author":"Lederer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.117768_bib3","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/S0140-6736(17)30866-8","article-title":"Idiopathic pulmonary fibrosis","volume":"389","author":"Richeldi","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2025.117768_bib4","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1183\/09059180.00002512","article-title":"Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature","volume":"21","author":"Nalysnyk","year":"2012","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.ejmech.2025.117768_bib5","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1183\/13993003.01653-2015","article-title":"Incidence and prevalence of idiopathic pulmonary fibrosis in US adults 18-64 years old","volume":"48","author":"Raghu","year":"2016","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ejmech.2025.117768_bib6","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1164\/rccm.201006-0894CI","article-title":"Clinical course and prediction of survival in idiopathic pulmonary fibrosis","volume":"183","author":"Ley","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ejmech.2025.117768_bib7","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1183\/09031936.00185114","article-title":"Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review","volume":"46","author":"Hutchinson","year":"2015","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ejmech.2025.117768_bib8","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1513\/AnnalsATS.201404-145OC","article-title":"Increasing global mortality from idiopathic pulmonary fibrosis in the twenty-first century","volume":"11","author":"Hutchinson","year":"2014","journal-title":"Ann. Am. Thorac. Soc."},{"key":"10.1016\/j.ejmech.2025.117768_bib9","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ejmech.2025.117768_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107798","article-title":"Idiopathic pulmonary fibrosis: disease mechanisms and drug development","volume":"222","author":"Spagnolo","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2025.117768_bib11","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.117768_bib12","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1103690","article-title":"Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis","volume":"365","author":"Richeldi","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.117768_bib13","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1111\/resp.13024","article-title":"Pirfenidone and nintedanib for pulmonary fibrosis in clinical practice: tolerability and adverse drug reactions","volume":"22","author":"Galli","year":"2017","journal-title":"Respirology"},{"key":"10.1016\/j.ejmech.2025.117768_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.797292","article-title":"Idiopathic pulmonary fibrosis: an update on pathogenesis","volume":"12","author":"Mei","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.117768_bib15","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/j.1398-9995.2009.02305.x","article-title":"IPF: new insight on pathogenesis and treatment","volume":"65","author":"Harari","year":"2010","journal-title":"Allergy"},{"key":"10.1016\/j.ejmech.2025.117768_bib16","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1146\/annurev-pathol-042320-030240","article-title":"Pathogenic mechanisms underlying idiopathic pulmonary fibrosis","volume":"17","author":"Moss","year":"2022","journal-title":"Annu. Rev. Pathol. Mech. Dis."},{"key":"10.1016\/j.ejmech.2025.117768_bib17","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1165\/rcmb.2022-0021OC","article-title":"Antifibrotic drug nintedanib inhibits CSF1R to promote IL-4-associated tissue repair macrophages","volume":"68","author":"Watson","year":"2023","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.ejmech.2025.117768_bib18","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1165\/rcmb.2017-0154OC","article-title":"Deletion of c-FLIP from CD11bhi macrophages prevents development of bleomycin-induced lung fibrosis","volume":"58","author":"McCubbrey","year":"2018","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.ejmech.2025.117768_bib19","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.cell.2018.09.009","article-title":"Lung single-cell signaling interaction map reveals basophil role in macrophage imprinting","volume":"175","author":"Cohen","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2025.117768_bib20","first-page":"1","article-title":"Microcystin-LR ameliorates pulmonary fibrosis via modulating CD206+ M2-like macrophage polarization","volume":"11","author":"Wang","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejmech.2025.117768_bib21","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12964-018-0300-8","article-title":"M2 macrophages promote myofibroblast differentiation of LR-MSCs and are associated with pulmonary fibrogenesis","volume":"16","author":"Hou","year":"2018","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.ejmech.2025.117768_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.678457","article-title":"Roles of macrophage polarization and macrophage-derived miRNAs in pulmonary fibrosis","volume":"12","author":"Kishore","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2025.117768_bib23","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2152\/jmi.60.175","article-title":"Targeting platelet-derived growth factor as a therapeutic approach in pulmonary fibrosis","volume":"60","author":"Nishioka","year":"2013","journal-title":"J. Med. Investig."},{"key":"10.1016\/j.ejmech.2025.117768_bib24","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1165\/rcmb.2013-0455OC","article-title":"Role of platelet-derived growth Factor\/platelet-derived growth factor receptor axis in the trafficking of circulating fibrocytes in pulmonary fibrosis","volume":"51","author":"Aono","year":"2014","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.ejmech.2025.117768_bib25","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.cytogfr.2004.03.006","article-title":"Regulation of PDGF and its receptors in fibrotic diseases","volume":"15","author":"Bonner","year":"2004","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.ejmech.2025.117768_bib26","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1089\/jir.2011.0079","article-title":"The fibroblast growth factor pathway and its role in the pathogenesis of lung disease","volume":"32","author":"Dosanjh","year":"2012","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.ejmech.2025.117768_bib27","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.3390\/ijms19051269","article-title":"VEGF (vascular endothelial growth factor) and fibrotic lung disease","volume":"19","author":"Barratt","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2025.117768_bib28","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1183\/09031936.00152106","article-title":"Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis","volume":"29","author":"Chaudhary","year":"2007","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ejmech.2025.117768_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110183","article-title":"Src family kinases and pulmonary fibrosis: a review","volume":"127","author":"Li","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejmech.2025.117768_bib30","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1124\/jpet.114.216044","article-title":"Therapeutic targeting of src kinase in myofibroblast differentiation and pulmonary fibrosis","volume":"351","author":"Hu","year":"2014","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2025.117768_bib31","doi-asserted-by":"crossref","first-page":"L129","DOI":"10.1152\/ajplung.00261.2005","article-title":"Src protein tyrosine kinase family and acute inflammatory responses","volume":"291","author":"Okutani","year":"2006","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"10.1016\/j.ejmech.2025.117768_bib32","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.117768_bib33","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1165\/rcmb.2018-0098OC","article-title":"The tyrosine kinase inhibitor TAS-115 attenuates bleomycin-induced lung fibrosis in mice","volume":"60","author":"Koyama","year":"2019","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.ejmech.2025.117768_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.conctc.2021.100832","article-title":"Design of phase 2 study of TAS-115, a novel oral multi-kinase inhibitor, in patients with idiopathic pulmonary fibrosis","volume":"23","author":"Nishioka","year":"2021","journal-title":"Contemp. Clin. Trials Commun"},{"key":"10.1016\/j.ejmech.2025.117768_bib35","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1164\/rccm.202010-3832OC","article-title":"Saracatinib, a selective src kinase inhibitor, blocks fibrotic responses in preclinical models of pulmonary fibrosis","volume":"206","author":"Ahangari","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ejmech.2025.117768_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.604314","article-title":"A phase I, randomized, double-blind, placebo-controlled, single ascending dose, multiple ascending dose and food effect study to evaluate the tolerance, pharmacokinetics of Jaktinib, a new selective Janus kinase inhibitor in healthy Chinese volunteers","volume":"11","author":"Liu","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.117768_bib37","article-title":"A phase 2 trial of KD025 to assess efficacy, safety and tolerability in patients with idiopathic pulmonary fibrosis","volume":"197","author":"Averill","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ejmech.2025.117768_bib38","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2021-001060","article-title":"CC-90001, a c-Jun N-terminal kinase (JNK) inhibitor, in patients with pulmonary fibrosis: design of a phase 2, randomised, placebo-controlled trial","volume":"9","author":"Popmihajlov","year":"2022","journal-title":"BMJ Open Respir. Res."},{"key":"10.1016\/j.ejmech.2025.117768_bib39","doi-asserted-by":"crossref","first-page":"L525","DOI":"10.1152\/ajplung.00163.2007","article-title":"TGF-\u03b2-induced EMT: mechanisms and implications for fibrotic lung disease","volume":"293","author":"Willis","year":"2007","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"10.1016\/j.ejmech.2025.117768_bib40","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1182\/blood-2011-09-379214","article-title":"Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling","volume":"119","author":"Hume","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.117768_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106566","article-title":"Targeting CSF-1R represents an effective strategy in modulating inflammatory diseases","volume":"187","author":"Xiang","year":"2023","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2025.117768_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2020.153298","article-title":"Biochanin-A ameliorates pulmonary fibrosis by suppressing the TGF-\u03b2 mediated EMT, myofibroblasts differentiation and collagen deposition in in vitro and in vivo systems","volume":"78","author":"Andugulapati","year":"2020","journal-title":"Phytomedicine"},{"key":"10.1016\/j.ejmech.2025.117768_bib43","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1021\/acs.jmedchem.9b01912","article-title":"Novel class of colony-stimulating factor 1 receptor kinase inhibitors based on an o-Aminopyridyl alkynyl scaffold as potential treatment for inflammatory disorders","volume":"63","author":"Xie","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117768_bib44","doi-asserted-by":"crossref","first-page":"13588","DOI":"10.1021\/acs.jmedchem.1c00976","article-title":"Discovery of potent antiallergic agents based on an o-Aminopyridinyl alkynyl scaffold","volume":"64","author":"Xie","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117768_bib45","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1021\/acs.jmedchem.9b01912","article-title":"Novel class of colony-stimulating factor 1 receptor kinase inhibitors based on an o-Aminopyridyl alkynyl scaffold as potential treatment for inflammatory disorders","volume":"63","author":"Xie","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117768_bib46","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1146\/annurev-physiol-012110-142225","article-title":"Epithelial-mesenchymal interactions in pulmonary fibrosis","volume":"73","author":"Chapman","year":"2011","journal-title":"Annu. Rev. Physiol."},{"key":"10.1016\/j.ejmech.2025.117768_bib47","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1465-9921-6-56","article-title":"TGF-\u03b21 induces human alveolar epithelial to mesenchymal cell transition (EMT)","volume":"6","author":"Kasai","year":"2005","journal-title":"Respir. Res."},{"key":"10.1016\/j.ejmech.2025.117768_bib48","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.resinv.2020.01.003","article-title":"Nintedanib inhibits epithelial-mesenchymal transition in A549 alveolar epithelial cells through regulation of the TGF-\u03b2\/Smad pathway","volume":"58","author":"Ihara","year":"2020","journal-title":"Respir. Investig."},{"key":"10.1016\/j.ejmech.2025.117768_bib49","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20190103","article-title":"Transforming growth factor\u2013\u03b2 in tissue fibrosis","volume":"217","author":"Frangogiannis","year":"2020","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ejmech.2025.117768_bib50","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1016\/j.ejca.2006.09.015","article-title":"The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; A review","volume":"42","author":"Eskens","year":"2006","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejmech.2025.117768_bib51","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.ctrv.2013.01.003","article-title":"Effect of inhibition of the FGFR\u2013MAPK signaling pathway on the development of ocular toxicities","volume":"39","author":"van der Noll","year":"2013","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.ejmech.2025.117768_bib52","first-page":"1","article-title":"Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management","volume":"8","author":"Shyam Sunder","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ejmech.2025.117768_bib53","first-page":"1395","article-title":"Severe adverse events associated with the use of second-line BCR\/ABL tyrosine kinase inhibitors: preferential occurrence in patients with comorbidities","volume":"96","author":"Valent","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.ejmech.2025.117768_bib54","doi-asserted-by":"crossref","first-page":"4774","DOI":"10.1158\/0008-5472.CAN-07-6307","article-title":"BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy","volume":"68","author":"Hilberg","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2025.117768_bib55","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.addr.2015.11.001","article-title":"Extracellular matrix structure","volume":"97","author":"Theocharis","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejmech.2025.117768_bib56","doi-asserted-by":"crossref","first-page":"L34","DOI":"10.1152\/ajplung.00007.2007","article-title":"Functional role and species-specific contribution of arginases in pulmonary fibrosis","volume":"294","author":"Kitowska","year":"2008","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425005331?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425005331?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T05:09:56Z","timestamp":1765602596000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425005331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":56,"alternative-id":["S0223523425005331"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117768","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of potent anti-idiopathic pulmonary fibrosis (IPF) agents based on an o-aminopyridinyl alkynyl scaffold","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117768","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117768"}}